Prostate cancer: Intermittent androgen deprivation-questions remain

Nature Reviews Urology

Volumn 6, Issue 8, 2009, Pages 412-414

  Keizman, Daniel ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANDROGEN; ANTIANDROGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTIBODY BLOOD LEVEL; BONE PAIN; CLINICAL STUDY; HUMAN; IMAGE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; TREATMENT RESPONSE; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; MALE; METHODOLOGY; MORTALITY; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANDROGEN ANTAGONISTS; ANDROGENS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77949362062     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.145     Document Type: Short Survey

References (10)

1. Calais da silva, F. e. et al. intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the south european Uroncological Group. Eur. Urol. 55, 1269-1277 (2009).
2. Thompson, C. A. et al. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 8, 474-487 (2003).
3. Keating, n. L., O'Malley, A. J. & smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448-4456 (2006).
4. Bruchovsky, n. et al. Quality of life, morbidity, and mortality results of a prospective phase ii study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin. Genitourin. Cancer 6, 46-52 (2008).
5. Akakura, K. et al. effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 71, 2782-2790 (1993).
6. sato, n. et al. intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 64, 341-345 (2004).
7. Miller, K. et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract #5015]. J. Clin. Oncol. 25 (Suppl. 18S), 5015 (2007).
8. Loblaw, D. A. et al. initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of Clinical Oncology practice guideline. J. Clin. Oncol. 25, 1596-1605 (2007).
9. Heidenreich, A. et al. european Association of Urology. eAU guidelines on prostate cancer. Eur. Urol. 53, 68-80 (2008).
10. Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest Oncology Group Trial 9346 (inT-0162). J. Clin. Oncol. 24, 3984-3990 (2006).